COST ANALYSIS OF THE CHRONIC HCV-RELATED CIRRHOSIS IN BULGARIA
Author(s)
Dimitrova M1, Petrova G2, Genov J3, Pavlov K3, Mitov K2, Savova A2
1Medical University-Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 3University Hospital “Queen Joanna-ISUL, Sofia, Bulgaria
OBJECTIVES: HCV infection is a leading cause of chronic liver disease with long-term complications - extensive fibrosis, cirrhosis and hepatocellular carcinoma. The objective of this study is to perform analysis of the cost of therapy of patients with chronic HCV - related cirrhosis in Bulgaria. METHODS: It is a combined prospective and retrospective, real life observational study of 301 patients with chronic HCV infection and cirrhosis monitored in the University Hospital “Queen Joanna-ISUL” for 3-year period (2012-2014). Data on demographic, clinical characteristics and healthcare resources utilization (hospitalizations, highly-specialized interventions, pharmacotherapy) was collected. Micro-costing approach was applied to evaluate the total medical costs. The points of view are that of the National Health Insurance Fund (NHIF), hospital and the patients. Collected cost data are from the NHIF and hospitals tariffs, patients, and from the positive dug list for medicines prices. Statistical processing was through descriptive statistics and Chi-squared test. RESULTS: CONCLUSIONS: HCV-related cirrhosis is resource demanding and implicit high direct medical costs as it is related with lots of hospitalizations and leads to complications acquiring additional treatment.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PIN41
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine)